Atara Biotherapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, ATRA, Atara Biotherapeutics Inc, priceseries

Atara Biotherapeutics Inc. Daily Stock Analysis
Stock Information
Open
9.00
Close
8.59
High
9.10
Low
8.54
Previous Close
8.85
Daily Price Gain
-0.26
YTD High
16.93
YTD High Date
Jan 3, 2022
YTD Low
8.54
YTD Low Date
Mar 7, 2022
YTD Price Change
-8.30
YTD Gain
-49.14%
52 Week High
20.04
52 Week High Date
Nov 4, 2021
52 Week Low
8.54
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-7.59
52 Week Gain
-46.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 3. 2017
14.20
Feb 21. 2017
14.96
11 Trading Days
5.32%
Link
LONG
Mar 8. 2017
17.30
Mar 15. 2017
19.03
5 Trading Days
10.02%
Link
LONG
Jan 5. 2018
18.50
Feb 2. 2018
33.88
19 Trading Days
83.14%
Link
LONG
May 11. 2018
42.75
May 29. 2018
48.81
11 Trading Days
14.18%
Link
LONG
Jan 30. 2019
36.17
Feb 21. 2019
38.33
15 Trading Days
5.98%
Link
LONG
Dec 6. 2019
13.99
Dec 19. 2019
15.11
9 Trading Days
8.03%
Link
LONG
May 15. 2020
10.77
May 26. 2020
11.81
6 Trading Days
9.67%
Link
LONG
Jun 22. 2020
11.84
Jul 13. 2020
14.19
14 Trading Days
19.85%
Link
LONG
Sep 8. 2020
13.46
Sep 21. 2020
15.04
9 Trading Days
11.73%
Link
LONG
Nov 9. 2020
14.40
Dec 9. 2020
23.53
21 Trading Days
63.41%
Link
LONG
Aug 20. 2021
12.63
Sep 8. 2021
14.95
12 Trading Days
18.35%
Link
LONG
Sep 17. 2021
16.08
Oct 8. 2021
16.97
15 Trading Days
5.52%
Link
LONG
Nov 1. 2021
16.51
Nov 10. 2021
17.36
7 Trading Days
5.12%
Link
Company Information
Stock Symbol
ATRA
Exchange
NasdaqGS
Company URL
http://www.atarabio.com
Company Phone
650-278-8930
CEO
Issac E. Ciechanover
Headquarters
California
Business Address
611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001604464
About

Atara Biotherapeutics, Inc. operates as a clinical stage biopharmaceutical company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Description

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading